Definition
Lexatumumab is a fully human monoclonal antibody that selectively binds to and activates the tumor necrosis factor‑related apoptosis‑inducing ligand receptor 2 (TRAIL‑R2, also known as death receptor 5 or DR5). By triggering this receptor, lexatumumab induces apoptosis in certain cancer cells.
Overview
Lexatumumab was developed by Human Genome Sciences (later incorporated into GlaxoSmithKline) as an investigational therapeutic agent for the treatment of malignant solid tumours. Pre‑clinical studies demonstrated its ability to promote tumor cell death and enhance the efficacy of chemotherapy and radiation. Clinical development proceeded to Phase I and Phase II trials in patients with advanced colorectal, non‑small‑cell lung, and pancreatic cancers, among others. Results showed limited anti‑tumour activity and the programme was subsequently discontinued, with no regulatory approval granted.
Etymology/Origin
The name follows the International Nonproprietary Names (INN) convention for monoclonal antibodies: the suffix “‑umab” denotes a fully human antibody, while the stem “‑lexa‑” is a unique identifier assigned by the World Health Organization to distinguish this specific agent.
Characteristics
- Type: Fully human IgG1κ monoclonal antibody.
- Target: TRAIL‑R2/DR5 (TNFRSF10B).
- Mechanism of action: Agonistic binding to TRAIL‑R2 activates the extrinsic apoptotic pathway, leading to caspase‑8 activation and downstream cell death.
- Molecular weight: Approximately 150 kDa, typical of IgG antibodies.
- Pharmacokinetics: In early clinical studies, the antibody displayed a half‑life of roughly 2–3 weeks after intravenous administration, consistent with other IgG1 antibodies.
- Clinical status: Development halted after Phase II trials; not approved for any therapeutic indication.
Related Topics
- TRAIL pathway: A signaling cascade involving TRAIL ligands and their receptors (DR4/DR5) that can induce apoptosis in cancer cells while sparing most normal tissues.
- Other TRAIL‑R agonist antibodies: Examples include mapatumumab (targeting TRAIL‑R1) and conatumumab (another TRAIL‑R2 agonist).
- Monoclonal antibody therapeutics: Broad class of biologic drugs engineered to bind specific antigens for therapeutic purposes.
- Apoptosis in cancer therapy: Strategies that aim to trigger programmed cell death in malignant cells as a treatment modality.